Free Trial
NASDAQ:CTKB

Cytek Biosciences Q3 2026 Earnings Report

Cytek Biosciences logo
$5.34 -0.04 (-0.74%)
Closing price 10/7/2026 04:00 PM Eastern
Extended Trading
$5.40 +0.07 (+1.22%)
As of 10/7/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytek Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.07
Beat/Miss
N/A
One Year Ago EPS
N/A

Cytek Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$52.95 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cytek Biosciences Announcement Details

Quarter
Q3 2026
Time
After Market Closes
Conference Call Date
Wednesday, November 4, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Cytek Biosciences Earnings Headlines

Cytek Biosciences (NASDAQ:CTKB) Hits New 52-Week High - Should You Buy?
Anthropic’s $40 million midterm move
Anthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating AI safeguards, American leadership, and transparency ahead of the midterms. Alexander Green, Chief Investment Strategist of The Oxford Club, says the move signals Anthropic's shift from a technical story to a political and financial force, especially as IPO talk builds. A publicly accessible vehicle lists Anthropic as its largest holding, alongside Databricks and Anduril, and can be purchased through an ordinary brokerage account.tc pixel
See More Cytek Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cytek Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cytek Biosciences and other key companies, straight to your email.

About Cytek Biosciences

Cytek Biosciences (NASDAQ:CTKB) develops and manufactures cell analysis technologies for research, clinical, and biopharmaceutical applications. The company is best known for its full-spectrum flow cytometry platform, which captures a broader range of fluorescent light signals than conventional flow cytometers and is designed to support the analysis of complex cell populations.

Cytek’s product portfolio includes the Aurora and Northern Lights flow cytometers, which are available in configurations intended for a range of laboratory requirements. The company also provides cell-analysis software, fluorescence reagents, panels, and related consumables that support applications such as immunology, oncology, infectious disease research, cell and gene therapy development, and other areas of biomedical research.

Founded in 2011 and headquartered in Fremont, California, Cytek serves customers worldwide through direct operations and distribution partners. Its systems are used by academic and government research institutions, pharmaceutical and biotechnology companies, clinical laboratories, and other organizations conducting advanced cell analysis. Cytek became a publicly traded company on the Nasdaq in 2021.

View Cytek Biosciences Profile